Immune checkpoint inhibitors (ICIs) targeting the PD‐1/PD‐L1 axis, either as monotherapy or in combination with chemotherapy, are now the cornerstone of the treatment of metastatic NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.